Vincent Fert

QIAGEN Marseille SA is a molecular diagnosis company, which focuses on the development and marketing of diagnostic tests in the field of oncology. Its products are used for diagnosis, prognosis and monitoring of patients with leukemia. The company was founded by Vincent Fert, Stéphane Debono, and Fabienne Hermitte on September 23, 1999 and is headquartered in Marseille, France.

Librophyt SAS discovers, develops and produces ground breaking small natural molecules through metabolic engineering in plants. The compay focuses on secondary metabolism in plants for drug discovery and biosynthesis applications. The firm serves the biopharmaceutical market. Librophyt was founded by Alain Tissier in 2003 and is headquartered in Saint Paul-Lez-Durance, France.

Part of QIAGEN NV, Ipsogen, Inc. is a company that develops and markets molecular diagnostic tests for leukemia and breast cancer. The company is based in Stamford, CT. The company was founded by Vincent Fert.

HalioDxinvest SAS develops and researches biotechnology products. The company was incorporated on October 17, 2014 and is headquartered in Marseille, France.

Theradiag SA engages in the distribution, development, and manufacturing of in vitro diagnostic and theranostics tests. It operates through the following segments: Theranostics and Diagnostics. The Theranostics segment offers solutions for patients treated with anti-tumour necrosis factor alpha. The Diagnostics segment includes products for anti-immunity, genetics, allergy, infectious disease, drug of abuse, other diagnoses, and instrumentation. The company was founded on December 29, 1986 and is headquartered in Croissy-Beaubourg, France.

Part of HalioDxinvest SAS, HalioDx SASU is a French company that offers a comprehensive suite of biomarker services to deliver integrated and interpreted data, uncovering the critical biomarkers that drive effective decision-making. The company is based in Marseille, France. The company's services include outsourcing assays such as NGS, qPCR, ELISA, IHC, and IVD testing to Veracyte. The company also offers Immunogram, a service that integrates multi-omic data sets into a single per patient view of key biomarker signatures specific to their own TME. Additionally, Veracyte, a unique multiplex tissue imaging and analysis approach, combines multiple technologies to characterize the tumor microenvironment. The company was founded in 2014 by Vincent Fert, who has been the CEO since 2014.

EuroBioMed engages as an association related to healthcare research, engineering innovation and support for companies and projects. It operates in the following business segments: teaching, fundamental, translational and clinical research, technological innovation centers, start-ups and, industrial success stories. The company was founded in 2009 and is headquartered in Marseille, France.